Wyser Capital

Wyser Capital is a Bengaluru-based early-stage backer of agentic automation and AI platforms for healthcare workflows. Check sizes are below $250k, consistent with pre-seed and very early seed participation. The firm has explicit AI thematic positioning and an explicitly healthcare-relevant lens. The input record cites Pype AI as a portfolio example.

The firm’s natural fit is with very early-stage technical founders building agentic AI products specifically for healthcare workflows, including clinical documentation automation, RCM and prior authorization automation, scheduling and intake agents, and operational workflow agents for providers and payers. The right founder profile is a technical team with credible AI engineering depth and a clear understanding of a specific healthcare workflow’s economics. Founders building general-purpose AI infrastructure, DTC consumer health, biotech, or pure non-AI software are not the natural target.

Geographically, Bengaluru remains India’s deepest AI engineering talent market, and Wyser’s local network can plausibly help founders recruit and accelerate technical product development. For Indian-anchored AI-first founders, the firm is a credible pre-seed partner. For non-Indian founders, the strategic logic depends on whether your team has any India presence; pure US-headquartered teams will find better fits in dedicated US AI seed funds.

The right entry path is a warm intro from a portfolio founder, a fellow Indian AI VC, or a senior engineer at one of the AI-native Indian companies. The firm reads partner-led decks and responds to clear agentic AI pitches with credible technical depth and specific workflow understanding. The pitch should lead with the agent architecture, the specific healthcare workflow being automated, the unit economics of the workflow today and post-automation, and a credible plan for early customer validation.

Caveats. Agentic AI is a fast-evolving category with significant model and infrastructure dependencies; founders should be transparent about technical risk, model dependencies, and the path to defensibility. The firm’s check size means Wyser should be a foundational early partner rather than a sole lead at larger rounds; plan follow-on capital strategy accordingly. The firm’s portfolio depth in agentic AI specifically is recent; reference calls with portfolio founders, including Pype AI, are essential. For very early-stage technical founders building agentic AI for healthcare workflows with Indian operational anchors, Wyser Capital is a credible thematic early partner; for non-AI or non-Indian founders, the fit is weaker.